A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study

Diana F. Nelson, Marie Diener-West, Alan S. Weinstein, David Schoenfeld, James S. Nelson, William T. Sause, Chu Huai Chang, Robert Goodman, Steven Carabell

Research output: Contribution to journalArticle

Abstract

This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. One hundred and forty-six evaluable patients were treated with conventional radiation therapy to 60.00 Gy in 6-7 weeks plus BCNU 80 mg/m2/d for 3 days every 8 weeks (XRT + BCNU). One hundred and forty-seven evaluable patients were treated with misonidazole 2.5 gm/m2 once a week for 6 weeks, radiation therapy to 60 Gy and BCNU (MISO + XRT + BCNU). Patients were stratified according to the prognostic factors of age, performance status, and histology. Distribution of these characteristics was comparable among the treatment groups. The median survival for XRT + BCNU was 55.0 weeks, and for MISO + XRT + BCNU 46.0 weeks (p = 0.35). With patients on a minimum dose of dexamethasone of 3 mg/d, misonidazole neurotoxicity included 8.8% peripheral neuropathy, 2.7% CNS toxicity, and a 0.68% ototoxicity. BNCU pulmonary toxicity occurred in 9.3% of patients who received 902-2062 mg/m2 of BCNU.

Original languageEnglish (US)
Pages (from-to)1793-1800
Number of pages8
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume12
Issue number10
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Misonidazole
Carmustine
surgery
Glioma
radiation therapy
Radiotherapy
toxicity
Therapeutics
histology
Peripheral Nervous System Diseases
Dexamethasone
dosage
Histology
Lung
Survival

Keywords

  • BCNU
  • Malignant glioma
  • Misonidazole
  • Radiation sensitizers
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery : Final report of an RTOG study. / Nelson, Diana F.; Diener-West, Marie; Weinstein, Alan S.; Schoenfeld, David; Nelson, James S.; Sause, William T.; Chang, Chu Huai; Goodman, Robert; Carabell, Steven.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 12, No. 10, 1986, p. 1793-1800.

Research output: Contribution to journalArticle

Nelson, Diana F. ; Diener-West, Marie ; Weinstein, Alan S. ; Schoenfeld, David ; Nelson, James S. ; Sause, William T. ; Chang, Chu Huai ; Goodman, Robert ; Carabell, Steven. / A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery : Final report of an RTOG study. In: International Journal of Radiation Oncology, Biology, Physics. 1986 ; Vol. 12, No. 10. pp. 1793-1800.
@article{3e2b1651718041739650f7691fc21d59,
title = "A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study",
abstract = "This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. One hundred and forty-six evaluable patients were treated with conventional radiation therapy to 60.00 Gy in 6-7 weeks plus BCNU 80 mg/m2/d for 3 days every 8 weeks (XRT + BCNU). One hundred and forty-seven evaluable patients were treated with misonidazole 2.5 gm/m2 once a week for 6 weeks, radiation therapy to 60 Gy and BCNU (MISO + XRT + BCNU). Patients were stratified according to the prognostic factors of age, performance status, and histology. Distribution of these characteristics was comparable among the treatment groups. The median survival for XRT + BCNU was 55.0 weeks, and for MISO + XRT + BCNU 46.0 weeks (p = 0.35). With patients on a minimum dose of dexamethasone of 3 mg/d, misonidazole neurotoxicity included 8.8{\%} peripheral neuropathy, 2.7{\%} CNS toxicity, and a 0.68{\%} ototoxicity. BNCU pulmonary toxicity occurred in 9.3{\%} of patients who received 902-2062 mg/m2 of BCNU.",
keywords = "BCNU, Malignant glioma, Misonidazole, Radiation sensitizers, Radiation therapy",
author = "Nelson, {Diana F.} and Marie Diener-West and Weinstein, {Alan S.} and David Schoenfeld and Nelson, {James S.} and Sause, {William T.} and Chang, {Chu Huai} and Robert Goodman and Steven Carabell",
year = "1986",
doi = "10.1016/0360-3016(86)90321-4",
language = "English (US)",
volume = "12",
pages = "1793--1800",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery

T2 - Final report of an RTOG study

AU - Nelson, Diana F.

AU - Diener-West, Marie

AU - Weinstein, Alan S.

AU - Schoenfeld, David

AU - Nelson, James S.

AU - Sause, William T.

AU - Chang, Chu Huai

AU - Goodman, Robert

AU - Carabell, Steven

PY - 1986

Y1 - 1986

N2 - This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. One hundred and forty-six evaluable patients were treated with conventional radiation therapy to 60.00 Gy in 6-7 weeks plus BCNU 80 mg/m2/d for 3 days every 8 weeks (XRT + BCNU). One hundred and forty-seven evaluable patients were treated with misonidazole 2.5 gm/m2 once a week for 6 weeks, radiation therapy to 60 Gy and BCNU (MISO + XRT + BCNU). Patients were stratified according to the prognostic factors of age, performance status, and histology. Distribution of these characteristics was comparable among the treatment groups. The median survival for XRT + BCNU was 55.0 weeks, and for MISO + XRT + BCNU 46.0 weeks (p = 0.35). With patients on a minimum dose of dexamethasone of 3 mg/d, misonidazole neurotoxicity included 8.8% peripheral neuropathy, 2.7% CNS toxicity, and a 0.68% ototoxicity. BNCU pulmonary toxicity occurred in 9.3% of patients who received 902-2062 mg/m2 of BCNU.

AB - This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. One hundred and forty-six evaluable patients were treated with conventional radiation therapy to 60.00 Gy in 6-7 weeks plus BCNU 80 mg/m2/d for 3 days every 8 weeks (XRT + BCNU). One hundred and forty-seven evaluable patients were treated with misonidazole 2.5 gm/m2 once a week for 6 weeks, radiation therapy to 60 Gy and BCNU (MISO + XRT + BCNU). Patients were stratified according to the prognostic factors of age, performance status, and histology. Distribution of these characteristics was comparable among the treatment groups. The median survival for XRT + BCNU was 55.0 weeks, and for MISO + XRT + BCNU 46.0 weeks (p = 0.35). With patients on a minimum dose of dexamethasone of 3 mg/d, misonidazole neurotoxicity included 8.8% peripheral neuropathy, 2.7% CNS toxicity, and a 0.68% ototoxicity. BNCU pulmonary toxicity occurred in 9.3% of patients who received 902-2062 mg/m2 of BCNU.

KW - BCNU

KW - Malignant glioma

KW - Misonidazole

KW - Radiation sensitizers

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0022997570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022997570&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(86)90321-4

DO - 10.1016/0360-3016(86)90321-4

M3 - Article

C2 - 3531110

AN - SCOPUS:0022997570

VL - 12

SP - 1793

EP - 1800

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 10

ER -